₹513 crore market cap, ₹222 stock price, ROCE of 60%, ROE of 45%, debt zero, and profits growing faster than Instagram fitness influencers. Influx Healthtech is that rare SME where the balance sheet looks cleaner than a newly sterilized GMP plant. In the last reported half-year results, the company clocked ₹67 crore in revenue and ₹10 crore in PAT. That’s not “SME jugaad numbers,” that’s proper muscle mass.
Three-month return is ~15.5%, valuation P/E sits around 29, and despite being just five years old, Influx behaves like a disciplined midcap that already knows SEBI is watching. Nutraceuticals dominate revenues like whey dominates gym bags, but cosmetics, ayurvedic, veterinary, and homecare quietly sit in the corner waiting for their glow-up.
If you like asset-light CDMO models, high utilization plants, and promoters who haven’t yet discovered the joy of pledging shares, you might want to sit down for this one. The numbers don’t scream — they flex.
2. Introduction – Welcome to India’s Contract Manufacturing Gym
Influx Healthtech was incorporated in September 2020, right when the world decided immunity boosters were more important than wedding expenses. Perfect timing. While everyone else was panic-buying sanitizers, Influx quietly built a B2B contract manufacturing model focused on nutraceuticals, cosmetics, ayurvedic products, veterinary supplements, and even homecare cleaners.
This is not a D2C influencer brand begging you to “use my code.” This is the boring-but-beautiful backend CDMO business. They formulate, manufacture, pack, and commercialize products for other brands. No marketing drama, no Instagram reels, just factories running at 90%+ utilization like obedient employees.
The company listed on NSE SME in June 2025, raised ₹58.5 crore via IPO, and immediately started talking about capex instead of Lamborghinis. That alone deserves a slow clap. With revenues scaling from ₹59 crore in FY22 to ₹124 crore TTM, and PAT growing at a 3-year CAGR of ~44%, Influx looks less like a startup and more like a well-fed operations machine.
But is this growth sustainable, or is it just early-stage adrenaline? Let’s put on our auditor glasses and dig in.
3. Business Model – WTF Do They Even Do?
Think of Influx Healthtech as the factory behind your favorite nutraceutical brand. They don’t sell to you. They sell to brands who sell to you.
They operate as a Contract Development and Manufacturing Organization (CDMO). Translation for lazy investors: clients come with an idea (“bro, I want mango-flavored collagen gummies”), and Influx handles formulation, regulatory compliance, manufacturing, and packaging. Client focuses on branding, Influx focuses on not blowing up the batch.
Ayurvedic / Herbal (2.92%) Capsules, oils, creams, powders — traditional medicine with modern packaging.
Veterinary Supplements (1.08%) Products for dogs, cats, cattle, birds. Because even pets now need supplements.
Homecare (0.05%) Cleaners, disinfectants, surface sprays. Small but expandable.
They operate three leased manufacturing units in Thane, all certified with WHO-GMP, ISO, FDA, HACCP, Halal — basically every alphabet that makes regulators happy.
Here’s the kicker: capacity utilization is already 90%+ in core units. That’s why capex is coming. Growth is not optional anymore.
Question for you: would you rather own a brand that spends on ads, or the factory that prints money quietly?
4. Financials Overview – Numbers Doing Push-Ups
The latest official heading clearly states “Half Yearly Results”. So EPS annualisation rule: Half-Yearly EPS × 2. Locked. No jugaad later.
Half-Yearly Performance Comparison (₹ Crore)
Metric
Latest HY (Sep 2025)
YoY HY (Sep 2024)
Prev HY (Mar 2025)
YoY %
QoQ %
Revenue
67
48
57
39.6%
17.5%
EBITDA
15
9
11
66.7%
36.4%
PAT
10
6
8
66.7%
25.0%
EPS (₹)
4.32
3.10
4.21
39.4%
2.6%
Annualised EPS = 4.32 × 2 = ₹8.64
Commentary time: Revenue is growing fast, but profits are growing faster. That’s margin expansion, not discount-driven nonsense. OPM improved to ~22%, which is very healthy for a manufacturing CDMO. PAT growth of ~67% YoY tells you operating leverage has entered the chat.
Are these numbers perfect? No. Are they impressive for a 2020-incorporated SME? Absolutely.
5. Valuation Discussion – Fair Value Range (No Crystal Ball)
